City University of New York (CUNY)

CUNY Academic Works
Dissertations, Theses, and Capstone Projects

CUNY Graduate Center

5-2015

The Effects of Cooling During Gait on Gait Endurance in Persons
with Multiple Sclerosis Using the Six Minute Walk Test
Meghan Higgins
Graduate Center, City University of New York

Esther Sosowsky
Graduate Center, City University of New York

Elisheva Zinberg
Graduate Center, City University of New York

How does access to this work benefit you? Let us know!
More information about this work at: https://academicworks.cuny.edu/gc_etds/816
Discover additional works at: https://academicworks.cuny.edu
This work is made publicly available by the City University of New York (CUNY).
Contact: AcademicWorks@cuny.edu

The Effects of Cooling During Gait on Gait Endurance in Persons with
Multiple Sclerosis Using the Six Minute Walk Test

By
MEGHAN HIGGINS
ESTHER SOSOWSKY
ELISHEVA ZINBERG

A capstone project submitted to the Graduate Faculty in Physical Therapy in partial fulfillment of the
requirements for the degree of Doctor of Physical Therapy, The City University of New York
2015

i

This manuscript has been read and accepted for the
Graduate Faculty in Physical Therapy in satisfaction of the
capstone project requirement for the degree of DPT

Herb Karpatkin, PT, DSc
_____________________________________

________________________
Date

_____________________________________
Chair of Examining Committee (Advisor)
Jeffrey Rothman, PT, Ed.D.
_____________________________________

_________________________
Date

______________________________________
Executive Officer

THE CITY UNIVERSITY OF NEW YORK

ii

ABSTRACT
THE EFFECTS OF COOLING DURING GAIT ON GAIT ENDURANCE IN PERSONS WITH
MULTIPLE SCLEROSIS USING THE SIX MINUTE WALK TEST
By
Meghan Higgins
Esther Sosowsky
Elisheva Zinberg

Advisor: Professor Herb Karpatkin
Background: Persons with MS (pwMS) are limited in their mobility due to thermosensitivity.
Exercising at a sufficient volume and intensity to increase mobility can result in increased core
temperatures and resultant worsening of symptoms. The use of cooling garments to lower core
temperature has been found to be a successful means of allowing pwMS to exercise for longer
periods. Previous studies have relied on precooling for an extended period of time prior to
activity, to achieve improved exercise performance. Cooling during the performance itself, or
pericooling, may allow for similar performance gains to be realized without spending the time
needed for precooling.
Objectives: The purpose of this study is to examine the effects of pericooling on the Six Minute
Walk Test (6MWT) performance in pwMS. It was hypothesized that pwMS would have better
6MWT performance while wearing a cooling vest then compared to a noncooled condition. If
our hypothesis were correct, it would suggest that pwMS could achieve improved exercise
performance without engaging in precooling activities.
Methods: A randomized crossover design was used. Patients were randomized into cooled or
uncooled conditions. Cooled subjects would perform a 6MWT, donning a commercially
available cooling vest immediately prior to the walk. Walks would be performed once a week for
three weeks. Total 6MWT distance and minute-by-minute distance was recorded. Fatigue during
iii

the walk was measured using the Visual Analog Scale of Fatigue. Uncooled subjects would
perform the identical protocol without a cooling device. Following the three walks in one
condition, subjects would undergo a two-week washout period and then repeat the same protocol
in whatever condition they did not experience initially.
Results: Six females with mild MS (EDSS 2.67) completed the study. Pericooling resulted in
walking significantly, (F (1,17) = 4.63, p = .046, partial η2 = .214) farther in the cooled condition
(1257’) than in the uncooled condition (1154’). There was no significant difference in VAFS
scores between the 2 conditions.
Conclusions: Pericooling, delivered via a commercially available cooling vest resulted in better
6MWT scores than an uncooled condition in pwMS. As most studies of cooling in MS utilize
cooling prior to an activity, these results indicate an alternative and less time consuming means
of achieving the beneficial effects of cooling.

iv

Table of Contents
INTRODUCTION .......................................................................................................................... 1
PURPOSE …………………………….…………………………………………………15
METHODOLOGY………………………………………………………………………………16
RESEARCH DESIGN…………………………………………………………………..16
SUBJECTS………….…………………………………………………………………...16
PROCEDURES.…….…………………………………………………………………...16
RESULTS………………………………………………………………………………………..19
DEMOGRAPHICS AND SUBJECT CHARACTERISTICS…………………………...20
DISCUSSION……………………………………………………………………………………25
MECHANISMS………………………………………………………………………….25
LIMITATIONS…………………………………………………………………………..30
FUTURE STUDIES……………………………………………………………………..33
CLINICAL SIGNIFICANCE……………………………………………………………34
CONCLUSION…………………………………………………………………………………..35
APPENDIX………………………………………………………………………………………36
APPENDIX A: RECRUITMENT FLIER……………………………………………….36
APPENDIX B: CONSENT TO PARTICIPATE IN A SCREENING PROCESS ….…..37
APPENDIX C: CONSENT TO PARTICIPATE AS A RESEARCH SUBJECT……….40
APPENDIX D: SCREENING QUESTIONS AND SUBJECT DEMOGRAPHIC
INFORMATION…………………………………………………………………………44
APPENDIX E: FATIGUE SEVERITY SCALE (FSS)…………………………….……45
APPENDIX F: MULTIPLE SCLEROSIS IMPACT SCALE (MSIS-29)………………46
APPENDIX G: DATA ENTRY TABLE………………………………………………..48
APPENDIX H: VISUAL ANALOG FATIGUE SCALE……………………………….48
REFERENCES…………………………………………………………………………………..49

v

List of Tables
TABLE 1: Demographics and Clinical Characteristics of Participants (n=6)… ………………20
TABLE 2: Subject Demographics & Characteristics……………………….… ………………20
TABLE 3: 6MWT minute by minute walking distance and VAFS in cooled condition..……...21
TABLE 4: 6MWT minute by minute walking distance and VAFS in uncooled condition.....…22

vi

List of Figures
FIGURE 1: Methodology Flow Chart ………...………………………………………………..18
FIGURE 2: Mean 6MWT Distance Cooled Vs. Uncooled……..……………….….…………..23
FIGURE 3: Mean Difference in VAFS Cooled Vs. Uncooled…………..………...….………...23
FIGURE 4: Mean 6MWT Distance Cooled Vs. Uncooled Subjects 1-6 ……........………........24

vii

INTRODUCTION

Multiple Sclerosis (MS) is a chronic neurological disease, which involves inflammation,
axonal demyelination, and oxidative stress (Romme Christensen et al., 2013) in the central
nervous system that can be relapsing and remitting or progressive (Frohman, Davis, & Frohman,
2011). While the etiology of the demyelinating lesions is unclear, these lesions have been shown
to be in both gray and white matter and are the primary cause of neurological and physical
symptoms (Lucchinetti et al., 2011).
Research suggests that demyelinating lesions result in scar tissue, which leads to changes
in axonal physiology, loss of saltatory properties of electrical conduction, reduction in
conduction velocity, and a predisposition to conduction block (Frohman et al., 2011). This can
be especially disruptive to the propagation of action potentials, which need to travel across
myelin sheath gaps known as nodes of Ranvier. Nodes of Ranvier in healthy myelinated axons
are typically about one micrometer in length. The physiology of the myelinated axons allows for
a current that is between three and seven times greater than necessary to produce an action
potential. This excess is known as the safety factor (Smith & McDonald, 1999). However,
demyelinated axons have a much lower safety factor, which can be less than the current
itself. This decrease in the safety factor occurs because the current is no longer insulated by the
myelin sheath, which propels the current from one node to the next. The current is therefore
improperly directed along the axolemma and is dispersed, resulting in decreased conduction of
current to the next node. In addition, the widening of the nodes results in an increase in electrical
capacitance, further reducing the safety factor. As long as the safety factor is greater than one,
conduction will continue to occur, albeit at a slower rate than typical. Cases in which the safety
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factor is below one result in the failure of the conduction of the action potential from one node to
the next and can ultimately lead to a conduction block. In the event of a conduction block, the
individual will exhibit more severe symptoms, which are determined by the location of
demyelination. This demyelination can occur anywhere in the CNS for example, if the motor
neurons are affected, individuals will present with paralysis, and if the optic nerves are affected,
individuals will present with blindness (Smith, 1994).
While pwMS exhibit a variety of physical, cognitive, and neurological symptoms, the
most commonly experienced symptom is fatigue (Karpatkin, 2005). Fatigue can be primary or
secondary in nature. Primary fatigue is directly caused by the disease and can be the result of
axonal demyelination, inflammation, and degeneration of axons. Secondary fatigue is indirectly
caused by the disease and can be a result of sleep deprivation, pharmacological treatments, and
muscle disuse (Braley & Chervin 2010). Psychological factors also play a role in an individual’s
perception of fatigue (Kos, Kerckhofs, Nagels, D'Hooghe, & Ilsroukx, 2008).
Researchers have found that the clinical signs that accompany demyelination are
worsened by an increase in body temperature (Davis, Wilson, White, & Frohman, 2010). Davis
et al. suggests that an increase in body temperature affects the propagation of action potential and
the refractory period, and further contributes to conduction blocks. Primarily, an increase in
temperature shortens the action potential duration, thereby decreasing the amount of time for
depolarization of the demyelinated axolemma to its firing threshold. A temperature increase, in
conjunction with a decreased safety factor, increases the likelihood of a conduction block (Smith,
1994).
Heat exposure can have rapid effects on both physical and cognitive functions. It can
cause increased fatigue, decreased muscle strength, gait difficulties and an inability to think
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clearly (Geisler et al., 1996). Heat-induced exacerbations are found in approximately 60-80% of
MS patients and are usually reversible when the source of heat is removed (Davis et al., 2010).
Many individuals with MS are extremely sensitive to even small changes in temperature such
that exposure to the sun can cause an individual with a limping gait to be unable to walk, and a
hair dryer can exhaust an individual of energy entirely (Baker, 2002). Heat can have such severe
implications that one may need to be supported in a warm bath in order to prevent drowning
(Smith, 1994).
The effects of heat exposure in individuals with MS are exacerbated by deficits in neural
control of homeostatic body temperature, which impacts both autonomic and endocrine
thermoregulation by diminishing hypothalamic thermal response and sweat gland function
(Davis et al., 2010). Sweating, one of the primary heat dissipation mechanisms in the body is
paramount in maintaining internal temperature. Several studies have reported diminished
sweating responses in individuals with MS. Some studies tested subjects using quinizarin
powder, a gray substance that changes its shade to blue when exposed to sweat. Others delivered
a cholinergic agonist transdermally that stimulated eccrine sweat glands without the involvement
of the CNS. In addition, to ensure that thermoregulatory effector responses were being
sufficiently engaged, another study utilized a whole body heating tube-lined suit as opposed to a
locally induced agonist. Decreased sweat gland output was observed in all of the experiments,
suggesting that CNS lesions or impairments in neural control of sudomotor pathway could
contribute to reduced sweat function in individuals with MS (Davis et al., 2010).
Because exercise increases core body temperature, it can also result in heat exacerbations
for pwMS, and those with thermosensitivity can be less inclined to exercise. Fjelstad, Brittain,
Fjelstad, and Pardo (2010) studied the relationship between thermosensitivity and physical
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activity in 77 pwMS. Subjects indicated their level of physical activity through questionnaires,
and self-reported the presence or absence of temperature-induced symptoms. Those with selfreported thermosensitivity relayed considerably lower levels of physical activity than those
without (p<0.05). This demonstrates that thermosensitivity can be responsible for reduced
physical activity in pwMS.
Exercise, however, is extremely beneficial for pwMS, and various studies have
demonstrated the value of aerobic training for pwMS. In a study done by Petejan et al. (1996),
after a 15-week aerobic training program subjects demonstrated gains in maximum oxygen
consumption (VO2 max) and upper and lower extremity strength and decreases in skinfolds,
triglycerides, LDL’s, depression, and fatigue, suggesting that individuals with MS generate the
same responses to exercise as those without MS. In a longer study conducted by Rodgers and
Mulcare (1999) that coursed the span of six months, improvements were seen in VO2max,
whereas in a shorter study conducted by Mostert and Kesselring (2002) that coursed the span of
four weeks, improvements were not seen with VO2max. This suggests that the length of training
might be a factor in improving this parameter.
Resistance training has also been shown to be efficacious.

An eight-week lower

extremity resistance training study conducted by Harvey, Smith, and Jones (1999) revealed
improvement in chair transfer time. In addition, a three-month progressive resistive exercise
program study conducted by Kraft et al. (1996) showed improvement in functional tasks, such
as stair climbing and ambulation and increased muscle strength of the trained limbs (as cited in
Dalgas, Stenager, & Ingermann-Hansen, 2008).
Romberg et al. (2004) studied 95 pwMS to evaluate the effect of a six month combined
resistance and aerobic exercise program on walking speed (median EDSS: 6 for experimental
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group and 5.5 for control group). Patients in the experimental group were given an inpatient
exercise routine during the first three weeks and then proceeded to complete a progressive home
exercise program consisting of three strength training, and one aerobic routine each week from
weeks 4-20. One strength training routine was added for weeks 21-26. Patients kept a diary to
record adherence to these routines. Patients in the control group were asked to refrain from
making any major changes in their level of physical activity during these six months. Walking
speed was assessed by measuring the time it took for subjects to perform the 25 Foot Walk Test
(25FWT) and 500 meter walk test (500MWT) at maximum speed. Walk time was significantly
decreased in both tests in the experimental group after the six months of exercise. Though
25FWT time also decreased in the control group, the change was much greater in the
experimental group. No change was observed in 500MWT time in the control group. This study
illustrates that exercise can significantly improve the walking speed in pwMS.
Exercise has various other benefits in addition to its physical implications. It can provide
significant psychological benefits for pwMS by giving them a feeling of control over their lives
(Johnson, 1996). Studies have shown that exercise can reduce the depression and anxiety
experienced by pwMS (Turner 2009). Exercise can also reduce secondary fatigue caused by
disuse (Karpatkin, 2005). However, pwMS may be prevented from reaping the benefits of
exercise due to their sensitivity to temperature elevation.
Cooling prior to exercise, also known as precooling, has been suggested as a means of
reducing this temperature elevation and allowing pwMS to exercise with fewer heat induced
symptoms. Cooling methods include drinking cold beverages, immersing one’s limbs in cold
water and wearing cooling garments (White, Wilson, Davis, & Petajan, 2000).

Ku,

Montgomery, Lee, Luna, and Webbon (1999) differentiate between cooling garments that use
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active and passive cooling. In an active cooling garment, such a liquid cooling garment, a liquid
coolant is circulated through the garment and then to a portable chiller or heat exchange unit
where it is cooled down again. In a passive cooling garment the temperature depression is
accomplished through ice packs in the pockets of the garment or the use of evaporative
cooling. Active cooling garments provide better temperature control and have been shown to be
a more effective means of cooling. However, passive cooling garments tend to be lighter, more
portable, easier to use, and less expensive than active cooling garments (Meyer-Heim et al.
2007).
In fact, cooling has been found to increase exercise endurance even in the general
population. Tyler and Sunderland (2011) performed a crossover study to explore the effect of
cooling via a cooling collar on the perceived level of thermal strain. They found that wearing the
cooling collar increased the time taken to reach volitional exhaustion and that the subjects in the
cooled condition could exercise longer before reaching identical levels of perceived exertion
despite having higher rectal temperatures and heart rates at this point. This study suggests that
the experience of feeling cool allows individuals to exercise longer despite higher body
temperature.
Subjective measures have been used to explore the effects of precooling on performance
in pwMS. Flensner and Lindencrona (1999) studied the effects of a cooling suit on the self-care
ability of MS patients. The quasi-experimental before-and-after single case study included ten
persons in variable stages of MS, who were instructed to wear a cooling cap and waist coat daily
for a period of at least four weeks. Data were collected using the MS Self-Care Activities of
Daily Living (ADL) Scale, open-ended interviews before and after the intervention, and daily
diaries. Six out of ten subjects reported marked improvements in their ability to walk indoors
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and outdoors and five out of ten reported significantly increased ability to move and transfer.
Additionally, five out of ten reported increased strength and energy in the performance of
activity. Flessner and Lindencrona (2002) studied 8 people in various stages of MS to determine
if the use of a cooling suit influenced their experience with fatigue in daily life. They used a
single case-control design approach in which the subjects were instructed to wear a cooling head
cap and waist coat for several sessions daily for at least four weeks. The outcomes were
measured through self-assessment using the Fatigue Impact Scale, open-ended interviews before
and after the intervention, and daily diaries. Seven out of eight subjects reported decreased
levels of muscular fatigue, and six out of eight reported that it was easier to participate in social
activities. Although subjective measures are valuable in reflecting a patient’s perception of
fatigue, more objective measures are necessary to quantify the actual benefits of cooling.
Several studies have used objective measures to determine the efficacy of using
precooling to diminish various MS symptoms. Feys et al. (2005) studied the effect of cooling on
intention tremors in 18 pwMS (Mean Expanded Disability Status Scale (EDSS of 5.8) who
exhibited an intention tremor in at least one upper limb. The subjects' forearms were cooled
down using a cryomanchet with cold liquid circulating inside to keep skin temperature
constant. In one group, the skin was cooled down to 18 degrees Centigrade (the deep cooling
group), and in another, it was cooled to 25 degrees Centigrade (the moderate cooling group).
Intention tremor was measured using a wrist step-tracking device, which measured wrist flexion
and extension as the subjects performed a directed task-the step tracking task and the finger-tonose test. Assessments were made prior to cooling, immediately post-cooling, and after 10, 20,
and 30 minutes had elapsed. The subjects in the deep cooling group did worse on the finger
tapping task right after cooling, but their performance returned to normal after ten minutes
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(p<.001). Their speed also decreased in the step tracking task, though it improved over the next
30 minutes of evaluation (p<.0001). The accuracy of this task increased initially but returned to
normal after ten minutes (p<.001). Both the path length and the number of changes in direction
(both of which were indicators of tremor) were significantly decreased in this group (p<.0001 for
both). The moderate cooling condition did not exhibit any significant changes in the finger
tapping test or in the performance of the step tracking task. However, subjects demonstrated
significantly reduced tremor amplitude immediately after cooling (p<.05) as well as reduced
tremor frequency.

These changes lasted throughout the three minutes of evaluation after

cooling. This study indicates that cooling can significantly decrease intention tremor in pwMS.
Schwid et al. (2003) performed a randomized crossover study to determine the acute and
chronic effects of a cooling suit on pwMS. Seventy-five pwMS (mean EDSS of 3.3) and heat
sensitivity participated in this experiment. To test the acute effects of cooling, patients were
randomly assigned to either low dose (75 degrees Fahrenheit) or high dose (55 degrees
Fahrenheit) cooling. After ten minutes of rest, patients wore the appropriate cooling garment for
60 minutes and then rested again for 30 minutes without the garment. Neurological assessments
were performed before cooling and after the 30-minute rest using the MS Functional Composite
(MSFC). To assess the chronic effects of cooling, half of the subjects were instructed to wear
the cooling garments, which were set at a high dose temperature, at home one hour a day for four
weeks.

The

remaining

subjects

wore

no

cooling

garment

and

were

simply

observed. Neurological assessments were performed before the cooling and then again at the
end of four weeks after a high dosed cooling period identical to the one performed in the acute
phase of the experiment. Subjects also filled out daily self-evaluation measures of fatigue and
neurological function using the Modified Fatigue Impact Scale (MFIS) and the Rochester
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Fatigue Diary (RFD) and by rating energy level, muscle strength and cognitive function on a
nine-point Likert Scale. The groups were reversed after a one-week washout period, and the
tests were repeated. In the acute phase of the experiment, a small improvement in the MSFC
was shown in the high dose cooling group (p=.0073) while the low dose group only exhibited a
trend toward improving (p=.087). In the chronic phase, subjects whom had been cooled for one
hour each day for a month improved on the MSFC after the acute cooling session (p=.041) while
those patients in the observational group showed no significant changes (p=.21). Patients
reported less fatigue on both the MFIS and the RFD (p<.001 for both) during the month of
cooling. Additionally, 75.3% of patients reported having more energy during the cooling month
as compared to 39.4% of the observational group (p<.0001), 57.8% of the cooled group reported
increased strength during this month as compared to 30.9% in the observational group, and
55.0% of the cooled patients reported cognitive improvements compared to 30.7% in the
observational month (p<.0001 for all three measures). This experiment shows that cooling can
be a useful way to decrease various symptoms of MS.
Syndulko, Woldanski, Baumhefner, and Tourtellotte (1995) performed two pilot
experiments, which studied the immediate and cumulative effects of cooling on functional
impairments due to MS.

Nine heat-sensitive individuals with MS participated in the first

experiment, which studied the immediate effects of cooling utilizing a single group repeated
measure design. The experiment consisted of a screening session comprised of a neurological
exam and testing sessions. The testing sessions involved an examination period both before and
after a resting period, which included a variety of tests for lower extremity speed, standing
balance, and tandem gait within parallel bars. On two of the three sessions, the subjects were
cooled for 90 minutes during the resting period using a different cooling garment on each day.
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No statistically significant changes of any measures were produced by either of the cooling
garments, which is in contrast to the results produced by other studies. These results can
possibly be attributed to the small temperature changes that these garments produced of -0.6+0.4 degrees Celsius and 0.5+-.25 degrees Celsius as well as the fact that a resting period alone in
an air-conditioned environment can produce a tympanic temperature drop of up to 0.4 degrees
Celsius. This finding may suggest that the non-cooled session was an unfit control for this
experiment since the air-conditioned environment alone can serve as a beneficial cooling
device.
The second experiment performed by Syndulko et al. (1995) studied the cumulative
effects of cooling on functional impairments due to MS. Seventeen thermosensitive individuals
with MS participated in the experiment, which used an unblinded, parallel group design. The
participants were initially divided into two groups: a low-high cooling group and a high-high
cooling group. The low cooling protocol produced larger temperature drops than expected of up
to -0.4 C and was therefore an invalid control, and a non-cooled group was later added. The
experiment involved a nine-week program. The first three weeks were baseline testing weeks in
which the subjects practiced at home walking, maintaining balance, etc. During the following
six weeks the subjects utilized one of two cooling protocols in addition to the home practice, and
subjects in the non-cooled group did the home practice without any cooling protocols. During
this six-week period, the subjects in the cooling group were cooled during their weekly
evaluations while those in the control group were not. There were statistically significant
improvements in both standing balance (p=.0091) and tandem gait (p=.0191) due to the
immediate effects of cooling. Eight out of 12 subjects reported that the cooling therapy produced
immediate improvement in function, ambulation, and increased energy lasting up to two to three
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hours after cooling. The tandem gait test showed improvement over time (p=.0062) as did lower
extremity coordination (p=.0302).

This experiment illustrates the positive immediate and

cumulative effects of cooling, however, it fails to address its effects on more functional gait
activities.
Numerous studies have been conducted to specifically assess the effect of precooling on
ambulation in pwMS. White et al. (2000) performed a randomized control trial testing the effect
of precooling on walking performance in six ambulatory individuals with chronic MS (mean
EDSS score of 3.1±0.9) who had self-reported thermosensitivity and fatigue. The research
consisted of two 30-minute sub-maximal exercise sessions (combined arm leg ergometry), one of
which was preceded by precooling using an emersion bath. The number of steps and time
required to walk 25 feet were recorded before, immediately after, and 30 minutes following the
exercise sessions. Results showed that the frequency of steps immediately after exercise was
significantly better for the precooled sample (P<.05). Though walk time also improved in the
cooled subjects, these results were of borderline significance (p=.057). In addition, subjects in
the precooled group reported fewer heat induced symptoms such as ataxia, blurred vision, foot
drop and had lower rates of perceived exertion (RPE) during exercise (12 precooled: 14 non
cooled, P < .05). Although the small sample size poses a limitation, this study suggests that
precooling may be a viable method of reducing exercise-induced fatigue in individuals with
MS.
Nilsegard, Denison, and Gunnarsson (2006) studied 43 heat-sensitive pwMS (median
EDSS score of 4.0) to determine the effect of wearing a commercially produced cooling vest on
various measures of gait. This study utilized a randomized crossover design, in which subjects
were tested before and after a 45-minute session of wearing this vest. The vest was cooled in a
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freezer at -20 degrees Celsius for one group and was left at 22 degrees Celsius for the other. The
primary measures were the ten and 30-meter timed walk, which evaluated the time and mean
stride length of the subjects walking ten and 30 meters respectively. Both speed and stride
length significantly improved in both the ten and 30-meter timed walk tests.

This study

illustrates that a cooling vest can successfully improve speed of ambulation in pwMS but fails to
address the effect of precooling on walking endurance.
Meyer-Heim et al. (2007) examined the short-term effects of pericooling, cooling during
an exercise activity, using a lightweight cooling-garment technology on the functional abilities of
20 thermosensitive individuals with MS (EDSS ≤ 6.5) in a single blinded, balanced cross over
study. During the assessments, the subjects wore a properly working cooling device on one day
and inoperable one for sham control on the other. The study measured walking capacities
(25FWT), body sway, muscle strength, and spasticity. The cooling garment was found to
significantly improve the 25FWT (p=.035), lower limb strength (p=.004 and p=.037), and MS
functional composite (MSFC) (p=.017). While, this study examined the effects of pericooling on
the walking abilities of thermosensitive individuals, it failed to address its effects on longer more
functional distances.
Coyle, Krupp, Doscher, Deng and Milazzo (1996) researched the effects of cooling on
the timed walk, muscle strength, and coordination. The study utilized a randomized cross over
trial to examine 11 ambulatory relapsing and remitting thermosensitive MS patients (mean EDSS
2.7 ± 0.6). The subjects participated in two 45-minute sessions using a cooling garment. The
cooling session lowered their core body temperatures by at least 1 degree Celsius, and the sham
cooling session lowered their core body temperatures by less than 0.5 degrees Celsius. The
subjects were evaluated before and after the cooling and sham cooling sessions. The variables of
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interest were 25FWT lower extremity strength, and coordination. After cooling the core body
temperature of the subjects by at least 1 degree Celsius, significant improvements were noted in
all evaluated areas. With the times walk test, 73% of cooled subjects improved by one to ten
seconds (p=.0010) while the sham cooling subjects exhibited no improvements. Additionally, in
the cooled group, muscle strength improved in both upper and lower extremity muscles
(p=.0010).

The study illustrates the effects of cooling on the ability of thermosensitive

individuals to walk short distances.
Grahn, Murray, and Heller (2008) studied the effects of cooling on walking longer
distances in pwMS. This study examined the effects of cooling one hand on the physical
capacity of ten independently ambulating individuals with chronic MS and a history of
thermosensitivity (midrange EDSS) using randomized paired trials. A baseline assessment
examined the subjects’ physical performance on a treadmill and ability to walk long
distances. During the subsequent sessions, the treadmill was adjusted to 65% of the maximum
workload. The cooling session involved placing one hand in the cooling device (18-21° C) prior
to the onset of treadmill activity and throughout the exercise. Mean exercise durations were
analyzed, and the cooling treatment extended the exercise duration by an average of 35%
(p<.0003). This study illustrates that hand cooling can improve the ability of pwMS to walk
long distances.
Although the study by Grahn et al. showed positive results, testing ambulation using a
treadmill is not necessarily generalizable to functional walking since treadmill walking differs
from over ground walking in many ways. Because the surface is in motion, some muscles are
more active than they would be on ground, while others are less active. Furthermore, on a
treadmill the surface is constant in contrast to over ground walking in which surfaces

13

vary. Lastly, on a treadmill, one will maintain a constant speed while with over-ground walking,
one’s speed will vary with time. Therefore, the use of a treadmill to measure the effects of
cooling on gait endurance will not be identical to the effects of cooling on gait endurance in
functional environments.
Reynolds, Short, Westwood, and Cheung (2011) looked at the effect of head and neck
cooling on both short term and long term ambulation in pwMS. The researchers utilized a
double blinded crossover design and tested six female MS patients (EDSS range: 2.5-6.5, no
mean recorded) with heat sensitivity. Participants were each subjected to the pre-cooling, sham
cooling, and no cooling conditions on three separate visits. In the cooled condition, participants
wore a head and neck cooling device for 60 minutes prior to ambulation testing and then
performed through the 6MWT, the 25FWT, and the Timed Up and Go Test (TUG). In the sham
cooling phase, they wore a similar device before testing that allowed the participants to
experience the cooling sensation without any significant decrease in body temperature, and in the
non-cooled condition, they simply rested for 60 minutes prior to testing. There was a significant
improvement in the 6MWT seen in the cooled group (p=.036) as compared to the other two
groups. TUG scores were better in both the sham and cooled group than the non-cooled group
(p=.004), and there was no significant difference in the 25FWT (p=.135). The authors concluded
that pre-cooling can improve ambulation in pwMS, though the small sample size limits the
reliability of this study.
Previous studies have examined the effects of both precooling and pericooling on short
distance ambulation, however, the effects of cooling on long distance ambulation has not been
well studied. While Grahn et al. (2008) studied the effects of pericooling on long distance
walking,

the

ambulation

measure

using

a

treadmill

doesn’t

reflect

a

functional
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environment. Reynolds et al. (2011) studied the effects of precooling on long distance
ambulation using the more functional 6MWT, but further studies are necessary due to the small
sample size. Additionally, pericooling may be a more practical form of cooling in the daily life
of an MS patient because it does not require extensive preparation before each
activity. Pericooling may also be a more effective form of cooling due to the constant presence
of a cooling source throughout activity.

PURPOSE
Persons with Multiple Sclerosis are known to have difficulty with ambulation
endurance. Because thermosensitivity is a prominent feature of MS, elevation of body
temperature generated by walking can contribute to these limitations. Cooling has been shown
to improve short distance walking in pwMS, but its effects on long distances are not well
studied. The purpose of our study is to examine the effects of peri-cooling on gait endurance in
pwMS. We hypothesize that the use of a cooling garment will significantly improve gait
endurance. If our hypothesis is proven correct, cooling during gait can be used to enhance both
therapeutic and functional environments, maximizing patient performance in activities that
involve walking.
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METHODOLOGY
RESEARCH DESIGN
This study utilized a randomized crossover design, in which subjects served as their own
controls.

SUBJECTS
A sample convenience consisting of 6 subjects were recruited from Herb Karpatkin
Physical Therapy in New York, NY using flyers detailing the nature of this study (see appendix
A).

Subjects signed informed consent forms (see appendices B and C), approved by the

Institutional Review Board at Hunter College. The inclusion criteria comprised of a definitive
diagnosis of MS, the ability to ambulate continuously for six minutes with or without a device,
and the ability to understand and sign an informed consent. Participants were excluded if they
had any type of orthopedic or cardiopulmonary condition preventing their ability to walk six
minutes, were using steroids or had an exacerbation of their MS-specific symptoms immediately
prior to or during the study.

PROCEDURES
During the initial session, participants filled out an intake form (see appendix D), detailing
subject demographics such as MS type, years since diagnosis, age, gender, EDSS level,
medications, and assistive devices. They also filled out a Fatigue Severity Scale (FSS) (see
appendix E) and the Multiple Sclerosis Impact Scale (MSIS-29) (see appendix F). Subjects were
randomly assigned into a cooled or uncooled group for the first phase using a lottery system.
Subjects were tested twice weekly for 3 weeks. Sessions began with a 15 minute seated rest
16

period, after which subjects were asked to rate their baseline fatigue using the Visual Analogue
Fatigue Scale (VAFS) (see appendix H). The testing then comprised of the 6MWT, in which the
subjects were asked to walk as far as they could at their best comfortable pace in six
minutes. All subjects were accompanied by an examiner, who guarded them throughout the
entirety of the 6MWT. The distance was measured minute by minute by another examiner who
followed the subject’s walking path with a measuring wheel. Fatigue was then assessed after the
6MWT using the VAFS, and the difference between the fatigue reported before and after the six
minute walk was recorded. The members of the cooled group donned a cooling vest
immediately preceding the 6MWT, which they wore for the duration of the test. The cooling
vest was constructed of canvas and held nine ice packs, weighing a total of 4 pounds. The
members of the uncooled group performed an identical procedure without the cooling
vest. After the three measurements were completed, there was a two-week washout period to
limit the training effects of the testing. There was then a crossover in which the subjects
switched groups, and testing was repeated in the opposite condition for another three sessions.
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Day 1: Demographics, Characteristics, EDSS, FSS, MSIS (n=6)
Initial Session
Randomized Allocation

Cooled Group

First Phase
(3 Sessions)
Once a week for
3 weeks

Washout Phase
(2 Weeks)

15 minute rest
VAFS Prior to 6 MWT
Sessions 1-3:6 MWT with
Cooling vest

Uncooled Group
15 minute rest
VAFS Prior to 6 MWT
Sessions 1-3: 6 MWT without
cooling vest

Post 6MWT VAFS

Post 6MWT VAFS

No data collected
(No exercise performed)

No data collected
(No exercise performed)

Groups Cross Over
Cooled group

Second Phase
(3 Sessions)
Once a week for
3 weeks

Uncooled group

15 minute rest
VAFS Prior to 6 MWT

15 minute rest
VAFS prior to 6 MWT

Sessions 4-6: 6 MWT with
Cooling vest

Sessions 4-6: 6 MWT without
Cooling vest

Post 6MWT VAFS

Post 6MWT VAFS

Figure 1: Methodology Flow Chart
EDSS, Expanded Disability Status Scale; FSS, Fatigue Severity Scale; VAFS, Visual Analogue Fatigue Scale; MSIS, Multiple Sclerosis
Impact Scale; 6MWT, 6 Minute Walk Test;
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RESULTS

The purpose of this study was to examine differences between exercise conditions (i.e.,
cooled versus uncooled) with regard to fatigue, length of walking time (in minutes), and the
percentage difference in walking time (in minutes) with a sample of six adult females diagnosed
with MS. The mean age of the six participants was 51.33 years (SD = 2.87), and ages ranged
from 32 to 69 years. The mean length of years since diagnosis was 20.50 years (SD = 2.53) with
length of years since diagnosis ranging from four to 35 years.
To determine if significant differences emerged across conditions with regard to the three
variables of fatigue, walking time, and percentage difference in walking time, a repeatedmeasures multivariate analysis of variance (MANOVA) was conducted. Due to the small sample
size, bootstrapping (using a replication sample of 1000) was employed. Bootstrapping is a
relatively common statistical procedure in MS studies, including clinical trials, with small
samples (see Humphreys, Drummond, Phillips, & Lincoln, 2013; Palacios, Alonso, BronnumHansen, & Ascherio, 2011; Saxton et al., 2013).
Because the repeated-measures MANOVA involved just two levels of repeated measures,
the assumption of sphericity was not relevant to this analysis. Results from the repeatedmeasures MANOVA showed a trend toward significance: Wilks λ (3,15) = 0.65, F(3,15) = 2.65,
p = .087, partial η2 = .346. An examination of the individual variables showed one significant
result with regard to walking time, F (1,17) = 4.63, p = .046, partial η2 = .214. In the cooled
exercise condition, participants walked an average of 1257.13 feet (SD = 375.50) whereas in the
uncooled exercise condition, participants walked an average of 1164.56 feet (SD = 302.81).
While fatigue scores decreased in the cooled exercise condition (M = -6.28, SD = 17.40) from the
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uncooled exercise condition (M = -1.39, SD = 14.84), this decrease in fatigue was not significant
F (1,17) = 1.14, p = .300, partial η2 = .063. The lack of significance was likely due to the large
variance in fatigue scores in both conditions, but especially in the cooled exercise condition.
There were no significant differences in exercise conditions with regard to percentage difference
in walking time across the cooled exercise condition (M = .58, SD = .01) and uncooled exercise
condition (M = .55, SD = .10), F (1,17) = 1.85, p = .192, partial η2 = .098.

DEMOGRAPHICS AND SUBJECT CHARACTERISTICS
Age, mean (SD)
Gender

x̅ 51.33, range 32-69 years (+2.87)
Male
Female

EDSS Score, mean
Type of MS

0
6
x̅ 2.67, range 1.5-4

PP
RR
SP
FSS
MSIS
Taking Anti-fatigue Meds
Taking Anti-spasticity Meds
Assistive device
Years since dx, mean (SD)

1
2
3
x̅ 3.76, range 1.78-5.22
x̅ 61.67, range 34-83
2
2
3
x̅ 20.5, range 4-35 years (+2.53)

Table 1: Demographics and Clinical Characteristics of Participants (n=6)

Subject
#

Age

Gender
(M/F)

Yrs. Since
Diagnosis

EDSS

FSS

MSIS29

AntiFatigue
Meds

Antispasticity
Meds

1

32

F

19

1.5

4.67

74

N/A

N/A

Betaseron

N/A

2

44

F

19

2.5

5.22

64

N/A

Baclofen

N/A

Walk aid

Prozac,
Thyroxin,
Tobias

AFO, Cane

3

69

F

35

4

2.56

58

N/A

N/A

4

60

F

33

2.5

3.67

57

N/A

N/A

5

58

F

4

2

1.78

34

N/A

N/A

6

45

F

13

3.5

4.67

83

Ampyra

Baclofen

Other Meds

N/A
Copaxone,
Insulin,
levothyroxine
Tysabri,
Ampyra

Assistive
Device

N/A

N/A
cane, orthotic

Table 2: Subject Demographics & Characteristics
MS, Multiple Sclerosis; EDSS, Expanded Disability Status Scale; FSS, Fatigue Severity Scale; RR, relapsing-remitting;
SP, secondary progressive; PP, primary progressive
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6 Minute Walk Test Cooled VAFS and
Distance Walked Per Minute
TRIAL
#

VAFS
(mm)

MINUTE
1 (ft.)

MINUTE
2 (ft.)

MINUTE
3 (ft.)

MINUTE
4 (ft.)

MINUT
E 5 (ft.)

MINUTE
6 (ft.)

6 minute
total (ft.)

1

-11

298.75

289.5

307.08

306.83

300.67

300

1802.83

2

-14

299.75

292.75

302.5

294.41

299.84

293.08

1782.33

3

20

333.83

331.63

334.04

332.16

333.5

330.17

1995.33

1

0

248.83

240

241.33

246.42

241.75

246.67

1465

2

0

249.83

241.83

243.25

245.92

241.17

226.41

1448.41

3

0

246.66

247.42

243

231.17

237.83

238.67

1444.75

1

20

174.08

182.33

196.5

183.09

178.75

192

1106.75

2

10

173.33

191.42

184.16

172.17

175.67

195.83

1092.58

3

9

175.41

198.67

191.83

190

190.75

188.92

1135.58

1

-46

168.3

200.53

200.42

200.41

212.09

201.66

1183.41

2

-20

174.08

199.17

207.58

201.83

221.42

219.58

1223.67

3

-36

180.83

214.83

220.84

221

221.25

221

1279.75

1

1

203.75

210.91

213.34

209.58

210.58

199.75

1247.91

2

0

197.33

202.17

203.58

210.83

204.09

190.08

1208.08

3

0

206.83

200.5

206.17

210.25

217.5

204.33

1245.58

1

-20

106.58

113.75

111.42

107.41

114.34

105.58

659.083

2

-11

100.83

104.08

97.09

103.75

103.66

105.17

614.58

3

-15

114.91

114.92

110.92

116.83

118.17

116.83

692.58

SUBJECT 1
COOLED

SUBJECT 2
COOLED

SUBJECT 3
COOLED

SUBJECT 4
COOLED

SUBJECT 5
COOLED

SUBJECT 6
COOLED

Table 3: 6MWT minute by minute walking distance and VAFS in cooled condition
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6 Minute Walk Test Uncooled VAFS and
Distance Walked Per Minute
TRIAL
#

VAFS
(mm)

minute 1
(ft.)

minute
2 (ft.)

minute
3 (ft.)

minute
4 (ft,)

minute
5 (ft.)

minute
6 (ft.)

6 minute
total (ft.)

SUBJECT 1
UNCOOLED

1

-4

255.75

263.71

256.62

260.92

257.91

271.5

1566.41

2

-6

255.08

243.58

254.17

251.92

247.91

249.34

1502

3

-5

248.16

256.17

253.17

250.16

243.84

247.58

1499.083

1

1

232.416

233.084

221.91

221.25

212.75

209.17

1330.58

2

3

279

256.16

255.84

252.66

241.17

235.75

1520.58

3

-1

262.91

262.09

253.25

246.66

251.09

295.16

1571.16

1

19

175.33

190.08

190.92

191.42

188.91

194.75

1131.4167

2

11

194.25

200

200.16

191.67

199.42

199.08

1184.58

3

21

181.91

178.67

175.25

174.75

167.33

167.34

1045.25

1

7

142.83

158.5

165.33

168

171.42

174

980.08

2

-45

145.58

166.42

169.83

177.92

180.41

180.42

1020.58

3

13

128.75

155.08

156.75

160.17

160.1667

167.9133

928.83

1

0

191.16

194.42

192.75

195

181.42

185.83

1140.58

2

0

192.83

213.92

213.83

233.08

225.34

208.58

1287.58

3

0

200.66

192.25

189.67

199.17

202.08

203.17

1187

1

-13

113.83

126.58

117.42

114.25

107.83

101.42

681.33

2

-16

136.83

145.08

136.84

136.25

124.25

136.58

815.83

3

-10

100.25

107.91

96.25

87.75

90.17

86.83

569.16

SUBJECT 2
UNCOOLED

SUBJECT 3
UNCOOLED

SUBJECT 4
UNCOOLED

SUBJECT 5
UNCOOLED

SUBJECT 6
UNCOOLED

Table 4: 6MWT minute by minute walking distance and VAFS in uncooled condition
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Mean 6 MWT Distance (ft)

Mean 6 MWT Distance Cooled
Vs. Uncooled
1280
1260
1240
1220
1200
1180
1160
1140
1120
1100

Cooled
Uncooled

Cooled

Uncooled

Figure 2: Mean 6MWT Distance Cooled Vs. Uncooled

Mean Difference in VAFS Cooled
Vs. Uncooled
Mean Difference in VAFS
(Post-Pre 6MWT)

0
-1

cooled

uncooled

-2
-3

cooled

-4

uncooled

-5
-6
-7

Figure 3: Mean Difference in VAFS Cooled Vs. Uncooled

23

6 Minute Mean Distance (ft)

6 MWT Mean Distance
Cooled Vs. Uncooled
2000
1500
1000
500
cooled

0

uncooled

Subjects

Figure 4: Mean 6MWT Distance Cooled Vs. Uncooled Subjects 1-6
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DISCUSSION

In this study, we examined the effect of pericooling on gait endurance in persons with
MS via the 6MWT. We hypothesized that the use of a cooling garment would significantly
improve gait endurance in our subjects. Though various previous studies examined the effect of
pre-cooling on gait (White et al., 2000, Nilsegard, Dension and Gunnarsson, 2006, Grahn,
Murray and Heller, 2008 etc.), we specifically studied the use of pericooling, which may be more
functional in therapy and daily living since it does not require extensive preparation before the
activity is executed.

Our results indicated that our hypothesis was correct and that the

application of a cooling vest during walking improved 6MWT scores compared to an uncooled
condition. Subjects walked significantly greater distances while wearing the vest and walked an
average of 1257.12 feet compared to 1164.56 feet in the uncooled condition (p = .046). The
mean VAFS score decreased in both conditions as subjects reported less fatigue after performing
the 6MWT. The decrease in fatigue was greater in the cooled condition, though this difference
was not statistically significant (p=.300). Additionally, when comparing the percentage of
distance covered each minute of the 6MWT, there was also no significant difference between the
two conditions (p =. 192).
MECHANISMS
MS is a chronic disease of the central nervous system, which involves axonal
demyelination, inflammation, and oxidative stress (Romme Christensen et al., 2013).
Demyelinating lesions in the central nervous system lead to the formation of scar tissue and
cause changes in axonal physiology, decreased conduction velocity, and a predisposition for
conduction blocks (Frohman et al., 2011). While pwMS can exhibit a wide range of physical,
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cognitive, and neurological symptoms, the most commonly experienced symptom is fatigue
(Krupp et al. 1988) .
For many pwMS, an increase in body temperature leads to worsening of symptoms. This
phenomenon, known as thermosensitivity, affects 60-80% of pwMS (Davis et al., 2010). Heat
can contribute to various impairments in pwMS, including increasing fatigue, decreasing
strength, and increasing gait deviations (Geisler et al., 1996). On a neuronal level, it has been
suggested that heat contributes to conduction blocks by altering the propagation and the
refractory period of the action potential (Smith, 1994). Furthermore, pwMS often have deficits
in thermoregulation, which can exacerbate this effect.
It is possible that the use of a cooling vest increased ambulation endurance in our subjects
by decreasing the effects of thermosensitivity. Physical activity, such as walking, increases core
temperatures. The increase in temperature can lead to increased fatigue, decreased strength, and
increased gait deviations limiting ambulation endurance. A cooling vest decreases body
temperature, thereby ameliorating these effects.
It is also possible that the cooled condition had a psychological impact on patients that
contributed to their improved ambulation. As Tyler and Sunderland (2011) concluded, the use of
a cooling collar can decrease perceived exertion during exercise in healthy individuals. This
suggests that cooling decreases perception of fatigue even in the general population.
Additionally, in the MS population specifically, most pwMS are aware that heat makes their
symptoms worse, and our subjects were aware that the vest was cold. Their increased distance
may have been in part due to the perception that they would perform better with the
vest. Similarly, simply wearing the vest, which was clearly the experimental condition, may
have geared them to ambulate greater distances.
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It is possible that the cooling vest also provided proprioceptive input which increased
balance or motor control in the cooled subjects. A study performed by DaCosta and McDonough
demonstrated that a weighted vest decreased lateral sway during gait in children with sensory
integration disorder (2005). It is possible that the cooling vest used in our study, which weighed
four pounds, also provided proprioceptive input that contributed to increased balance and gait
improvements. However, DaCosta and McDonough’s study involved children between the ages
of five and 12 whose deficits were specifically related to processing sensory information, and
therefore increased sensory input targeted these deficits. It is unclear if a weighted vest would be
helpful in a population such as ours in which the gait deficits are not due to a sensory integration
disorder.
The effect of using a weighted vest on gait in pwMS was examined in a 2014 study
performed by Gorgas et al. In this study, subjects were given selectively weighted vests, in
which the weight was distributed based on the balance deficits of each subject. The distribution
of weight was determined based on an assessment of lateral sway with perturbations in each
direction and was customized for each participant. Gorgas et al. found that wearing the weighted
vest increased velocity, cadence, and time spent in single leg support in both pwMS and
controls. However, it is unclear if the vest that we used in our study, which was standardized
and not individualized to the needs of each participant, would have a similar effect. In fact, it is
equally feasible that the vest used could have a negative impact on balance if the distribution of
weight was not optimal for a specific subject.
Though heat is known to increase fatigue in pwMS (Davis, Wilsons, White & Frohman,
2010), the decrease in fatigue in the cooled condition was not statistically significant in this study
(p=.300). Fatigue is a subjective measure that cannot easily be quantified, and its origin is not
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always definable. In pwMS, fatigue can be due to demyelination and axonal loss characterized
by the disease itself, or it can be induced by a variety of secondary factors. These include
difficulty sleeping, decreased activity levels, medication usage, depression, pain, and various
other psychological factors (Kos, Kerckhofs, Nagels, D’Hooghe & Ilsroukx, 2008). This study
could not control for the variety of factors that may have influenced fatigue.
Additionally, it is important to note that on average the patients in both conditions
reported decreased fatigue after the 6MWT. This suggests that the perception of fatigue was not
the limiting factor that led to decreased ambulation endurance in the uncooled condition.
However, it is important to note that the small sample size may have played a role in the reported
decrease in fatigue across both conditions. Despite bootstrapping, the small n limits
generalizability especially since fatigue is so subjective. A larger sample size would provide
more reliable data about the changes in fatigue during the 6MWT.
The finding that there was no significant difference in the percentage of distance covered
in each minute of the 6MWT across the two conditions may support the notion that fatigue was
not the prime limiting factor in ambulation endurance. If fatigue were the cause of decreased
ambulation, we would have expected a consistent decline in distance covered in each progressive
minute in the uncooled condition and more stable numbers in the cooled condition. However,
even in the uncooled condition, the percentages remained relatively stable throughout the
duration of the walk for many of the subjects.
Perhaps the decrease VAFS ratings with the 6MWT can be attributed to the
psychological influences on fatigue. As Noakes 2012 states “sensations of fatigue…. [are]
largely independent of the real biological state of the athlete at the time they develop...
Subconscious and conscious mental decisions made by winners and losers, in both training and
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competition, are the ultimate determinants of both fatigue and athletic performance.” Motivation
is an essential factor in fatigue perception. It is therefore possible that the excitement of
accomplishing the six minute walk led to a decreased perception of fatigue with walking in both
conditions as reflected by the VAFS.
This discussion highlights the multifactorial nature of fatigue and therefore, the inherent
difficulty in measuring fatigue in pwMS. It is interesting to note that the EDSS scores of our
subjects did not directly correlate with their FSIS scores, further emphasizing that the perception
of fatigue is not a representation of true disability. It is possible the 6MWT was not aggressive
enough to induce a perceptible degree of fatigue in these subjects. Some of the participants in
the study walk for longer periods of time regularly and perhaps would require a greater duration
of ambulation before the onset of fatigue. Interestingly, the only subject with a consistent
increase in fatigue throughout trials also had a significantly higher EDSS score than the other
subjects, reflecting that the increase in perceived fatigue with the 6MWT correlates with
decreased baseline walking ability.
Though fatigue was not perceived to increase, the decrease in mean walking distance in
the uncooled condition suggests that on some level fatigue did interfere with their walking
ability. However the subjective, multifactorial nature of fatigue limits our ability to quantify its
effect on walking performance. It is also possible that the other symptoms associated with
thermosensitivity, such as spasticity and gait deviations, were the main cause for the decrease in
ambulation distance rather than fatigue perception.

Cooling, which prevents the onset of

thermosensitive symptoms, ameliorates all of these effects allowing for increased walking
distance.
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LIMITATIONS
There were a number of limitations observed during this study. MS is widely variable in
its presentation, including symptom severity and frequency, age of onset, and affected areas of
the body. Additionally, there is variability in the patients’ ability to cope psychologically with
their disease. Though our study represented a wide range of MS presentations, a larger sample
size is needed to get a true sense of how cooling impacts pwMS as a whole, and therefore the
small sample size (six) limits the generalizability of this study. It is possible, for instance that
the decrease in fatigue with the 6MWT was due to specific characteristics of the individuals
studied, and that in a larger sample, the results would be different. Though the diversity of our
subjects adds to the generalizability of our results, a larger sample size is needed to obtain a more
accurate understanding of the effect of a cooling vest on pwMS.
Another limitation of this study was the possibility of a phenomenon called Hawthorne
Effect, whereby subjects of an experiment alter their behavior when they know they are being
examined, often in an effort to please the examiner or provide what they feel are the correct
results. Participants were patients of the faculty advisor for this research project and may have
discussed with him the effects of cooling on pwMS during their therapy sessions in the
past. Since he is a significant facilitator and advocate in their health and well-being, these
discussions could have influenced their performance based on an awareness of his hypothesis.
Reporting and assessment of fatigue on a VAFS is subjective and susceptible to varied
interpretation by the participants. Thresholds differ between subjects. What some subjects
consider exhaustion, others view as mildly low energy, suggesting that personality and
sensitivity may impact reporting of fatigue levels. There is also the possibility that these
interpretations can change from day to day depending on the variable presentation of
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psychological and physical symptoms with MS. A study performed by Flachenecker et al. in
2002 examined multiple scales used to measure fatigue in MS and found a poor correlation
between the scales due to the multifactorial nature of fatigue. The study found that depression
scores were highly correlated with fatigue since MS patients with depression showed
significantly higher FSS scores than those without. Additionally, the feeling of accomplishment
from having completed a task of importance (in this case, a research trial) may have diverted
attention from or even mitigated awareness of fatigue. This variability in the perception and
reporting of fatigue makes it a very difficult measure to collect with baseline consistency from
one trial to the next. Perhaps a quantifiable measure, such as change in body temperature, would
be beneficial to compare with the acquired measurement of distance walked since it eliminates
the process of participant interpretation.
Scheduling also posed a possible limitation to this study. Due to work and family
obligations, time of day that testing occurred differed among subjects, some of whom could only
come early in the morning, while others could only come later in the day or early
evening. Therefore, while some subjects were tested after a full night’s sleep, others may have
experienced a day of substantial activity prior to testing. However, testing times were consistent
with each individual, and therefore level of fatigue due to previous activity was relatively
consistent. Additionally, due to scheduling conflicts intervals between testing ranged from onetwo weeks.
Outdoor and testing environment temperature also contributed to the limitations of this
study. Even though all subjects underwent a 15 minute rest period before each walking trial,
there was variability in both weather and building temperature from week to week, often, but not
always, with an inverse relationship whereby colder outdoor temperatures yielded warmer indoor
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temperatures and vice versa. These direct environmental influences might have had an effect on
body temperature, varying the baseline from which cooling with the vest began.
The vest had multiple characteristics other than temperature, which makes it difficult to
isolate the effect of cooling on gait. The cooling vest used in this study, constructed out of
canvas, had nine pockets into which ice packs were placed during cooling trials. The weight of
the vest, though reported by all subjects to cause no discomfort or adverse response, presents a
limitation to the study as the trial that incorporated pericooling required an additional, though
nominal, load to the subjects. Conversely, the vest may have provided proprioceptive and
psychological benefits to its wearers, resulting in improved walking performance during
pericooling trials. Though this limits our ability to isolate the effect of cooling on gait, it
provides more information on the practical uses of the vest in the therapeutic context.
During the course of the study, there were two reported injuries due to falls outside of the
testing trials, which may have impacted walking performance. When questioned by the
researchers, however, the two subjects who had sustained the falls contended that they were able
to carry out the trial with no difficulty as a consequence of their injuries.
Recording the feet walked at each minute of the 6MWT was subject to human
error. Measurement was performed by following the walking path of the subject with a handheld wheel and recording how many feet the subject walked each minute. While the path was
linear and pre-planned with few direction changes, the trajectory of the wheel was prone to slight
lateral curving during its course. Possible measurement errors may have contributed to a small
amount of variation in the collected results.
Another possible limitation of the study was that some subjects engaged in conversation
with their walk test administrators during trials, while other subjects kept discussion to a
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minimum for the duration of the walk test. Since certain individuals are more naturally social, it
is unclear whether or not this difference in behavior had an affect on their walking
performance. While it may have distracted or placed unnecessary demands on the subject, thus
impeding performance, it may just as likely have put the subject at ease and improved
performance. To further eliminate external influence on performance, future testing might
encourage minimal or no conversation during the walk trial to encourage focus on the physical
task at hand. Conversely, the purpose of this study was to observe the effects of pericooling on
walking, and conversation with walking is customary and often necessary.
FUTURE STUDIES
In addition to increasing the sample size and regulating more factors during testing trials
such as time of day and weather, there are several considerations that might be addressed with
future studies. This same study could be conducted in which a cooled condition is compared to a
sham cooling. Sham cooling is a process in which subjects in the uncooled group wear vests that
provide a significantly lower level of cooling to evoke the perception of being cooled without the
associated physiological effects.

This would distinguish between the physiological and

psychological effects of cooling.. Likewise, to eliminate the extra weight of the cooling garment,
the walk test might be conducted in a corridor cooled to a specific and regulated
temperature. Additionally, all subjects may be required to wear the same outfits so that they
have an equivalent layer of insulation between their skin and the external temperature imposed
on them. To further quantify the subjects’ baseline and thermosensitivity, testers may consider
taking measurements of body or skin temperature to determine how affected each subject is by
the cooling process. Future studies can also compare precooling to pericooling to see if there is
any benefit to precooling over the more functional pericooling.
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Another consideration for testing the effects of cooling during gait might be to calculate
the number of steps taken during the 6MWT in addition to distance travelled. This measurement
takes into account individual stride lengths based on height and functional ability, and therefore,
provides a quantifiable and more individual report of walking response in both cooled and
uncooled trials. Additionally, future studies could explore the changes in gait kinematics with a
cooling vest to determine more precisely the mechanism by which cooling increases the
ambulation distance. Future studies could also explore the effect of cooling on other functional
measures, such as balance and coordination, and could examine the effect of cooling on longer
distance ambulation, which may be more likely to induce perceptible fatigue in ambulatory
individuals with MS.
CLINICAL SIGNIFICANCE
Pericooling is a time conserving approach in comparison to precooling. Pericooling does
not require individuals to arrange their schedules in order to set aside time to precool before
performing physical activity. Rather, pericooling allows the individual to don the vest just as
they are beginning the activity. As it is, many individuals with MS report that performing basic
ADLs is extremely time consuming and that they do not have the extra time to pre-cool as it
would make a simple task, such as going to a supermarket, a full day excursion. Pericooling can
be a very practical means by which pwMS can increase their productivity and maintain a more
active and functional lifestyle without requiring them to set aside time to precool. Additionally,
the individual can spontaneously decide to participate in an activity without extensive
preparation.
The use of a cooling vest for pericooling can also have practical implications during
physical therapy sessions as it can effectively manage heat related symptoms and allow the
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individual to ambulate more functional distances. This will allow physical therapy sessions to be
more productive since it doesn’t require the individual to don the vest prior to the session, a task
that can be very time consuming and require the individual to arrive earlier.
Cooling vests are a very practical means of decreasing core temperature and lessening the
effects of thermosensitivity. The vests contain multiple insulated pockets that hold the ice packs.
They are lightweight (four pounds) and can be worn over clothing to provide cooling relief that
can last up to a few hours. Individuals can order multiple sets of ice packs, which can be stored
in the freezer for use at any time. Furthermore, the vests are extremely affordable, and many
programs, such as the MSAA Cooling program, offer the vests free of charge for pwMS.

CONCLUSION
Many individuals with MS are heat sensitive and experience fatigue when their core
temperature rises with exercise. This affects their ability to ambulate functional distances. Our
results show that the use of a cooling vest during ambulation has positive effects on ambulation
distance. This can have important implications for ameliorating the effects of thermosensitivity
and improving exercise tolerance. The use of a cooling vest is a convenient and affordable
intervention that does not require extensive preparation and can therefore be a practical
intervention. Future studies are necessary to ascertain if there is any advantage to precooling
over pericooling.
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APPENDIX
APPENDIX A: RECRUITMENT FLIER

Do you want to contribute to
MS research?
Volunteers needed for a study to determine the effect
of using a cooling vest on gait endurance in persons
with Multiple Sclerosis.
Participant requirements:
 Must be able to walk for 6 minutes unassisted with or
without an assistive device


Must have had no exacerbations within the last 3 months.



Must not be currently taking steroidal medication.



Must be available January-April 2014.

Study to be conducted at:
Hunter College Brookdale Health Science Campus
425 East 25th Street New York, NY 10010
*Travel expenses will be reimbursed.
If interested, contact:
Herb Karpatkin, PT, Dsc
Telephone: 212 396 7115
Email: Hkarpatk@hunter.cuny.edu
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APPENDIX B: CONSENT TO PARTICIPATE IN A SCREENING PROCESS
Hunter College
Program in Physical Therapy
City University of New York
Consent to Participate in a Screening Process
Investigators:
Herbert I. Karpatkin, PT, DSc.
Esther Sosowsky, SPT
Meghan Higgins, SPT
Elisheva Zinberg, SPT
Hunter College, Program in Physical Therapy
City University of New York
212-481-5051
Purpose and Background
Dr. Herbert Karpatkin, PT DSc is a professor at Hunter College in the Physical Therapy
Department. Esther Sosowsky, Meghan Higgins, and Elisheva Zinberg are doctoral students in
the Physical Therapy Program at Hunter College. They are conducting a study examining the
effects of cooling on gait endurance in persons with multiple sclerosis (MS). You are being
asked to participate in the screening process to determine eligibility for this study that will help
determine if wearing a cooling garment while walking allows persons with MS to walk longer
distances. You were selected for participation because you are a person with MS over 18 years of
age who walks as a regular means of transportation. There will be an anticipated 15 subjects that
will participate in this screening process. Your participation in the screening process is voluntary.
You may choose to not participate from the start and you may choose to stop at any time during
the process.
Procedures
On the first day, you will fill out a demographics questionnaire in Hunter College, after which
you will be interviewed by researchers to address any necessary follow up questions in order to
determine if you are eligible for the study. All subsequent sessions will also take place at the
Physical Therapy Department of Hunter College, at 425 east 25th street, basement level.




The screening process will involve answering questions about your medical history
including length of time with MS, medications, use of assistive devices for walking such
as canes, walkers, or splints, and whether you have a history of non-MS complications
such as a cardiac condition or orthopedic problems. The researchers will also look at
information from your medical records such as your Expanded Disability Scale Score
(EDSS) and MS Quality of Life score (MS QOL-54).
If your responses indicate that you are eligible, you will be asked to participate in this
study.
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If you are not eligible to participate, the information obtained from you during the
screening process will be omitted from this study and shredded to protect your privacy.

None of the procedures or questionnaires in this study is experimental. The only experimental
aspect of this study is the gathering of information for the purpose of analysis.
Risks
There are minimal risks to you for participating in the screening process of this study. The
screening process will require a maximum of 15 minutes of your time. Confidentiality of the
information will be safeguarded by de-identifying subjects and filing any identifying information
in a locked cabinet located at Dr. Karpatkin’s private practice. All identifying information will
be destroyed at the conclusion of the study. If deemed inelligable, or if at any time you choose
not to participate, data will be destroyed. You have the choice to refuse to answer any item in
any of the questionnaires or forms.
Benefits
There are no direct benefits to you resulting from the screening process.
Alternatives
The alternative to this study is nonparticipation without repercussions or penalties.
Financial Considerations
Other than the cost of travel to and from the Hunter College Brookdale Campus, there are no
costs incurred by you for participation in the screening process.
Confidentiality
Strict confidentiality will be maintained. Knowledge of your identity and participation in the
screening process will be limited to Dr. Karpatkin, the collaborating physical therapy students,
and IRB members and staff. Information about your participation will only be disclosed in the
event of an emergency requiring hospitalization, and in such a case will be disclosed to the
treating hospital physician and your primary care physician. Under expected non-emergency
circumstances, no individual identifying information about you will be disclosed. Where
possible, all identifying references about you will be removed and replaced by a numeric code.
Participation in this research is voluntary and involves minimal loss of your privacy. All
questionnaires and data about you that will be used in computer analysis will have number codes
rather than your name. Your name will not be recorded on the information or reported in any
scientific paper or professional meeting to protect your identity. All data will be reported in
aggregate (group) fashion at a professional meeting or in a scientific journal so that no one can
identify any information about you. If data is used for a publication in the medical literature or
for teaching purposes, no names will be used. A master list of code numbers as well as all other
data pertaining to you and other subjects will be kept confidential by the researchers and will be
stored in a locked file cabinet in the faculty research advisor’s office. Data that will be used for
computer analysis will be kept on a flash drive and only researchers involved in this study and
IRB members and staff will have access to the records and information about this study. All
original hardcopy data will be shredded seven years after completion of the study. The code key
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connecting names to numbers will be kept in the research office of Dr. Karpatkin. Confidentiality
will be maintained to the extent allowed by law.
Withdrawal
You may terminate your participation from the screening process prior to the start or at any time
during the process without penalty or repercussion.
Contact Information
If you have questions about the screening process, you can contact Dr. Karpatkin, at (212) 4815051. You should contact the Hunter College Human Research Protection Program (HRPP)
Office at hrpp@hunter.cuny.edu or 212-650-3053, if you have questions regarding your rights as
a subject or if you feel you have been harmed as a result of your participation in this research.
Signatures
I have read (or have had read to me) the contents of this consent form and have been encouraged
to ask questions. I have received answers to my questions. I give my consent to participate in
the screening process to determine if I am eligible to participate in the research study. I have
received (or will receive) a copy of this form for my records and future references.

______________________
Participant’s Name

___________________________
Signature

___________
Date

______________________
Researcher’s Name

___________________________
Signature

___________
Date
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APPENDIX C: CONSENT TO PARTICIPATE AS A RESEARCH SUBJECT
Hunter College
Program in Physical Therapy
City University of New York
Consent to Participate as a Research Subject
Investigators:
Herbert I. Karpatkin, PT, DSc.
Esther Sosowsky, SPT
Meghan Higgins, SPT
Elisheva Zinberg, SPT
Hunter College, Program in Physical Therapy
City University of New York
425 E 25th St
New York, NY 10010
212-481-5051
Purpose and Background
Dr. Herbert Karpatkin, PT DSc is a professor at Hunter College in the Physical Therapy
Department. Esther Sosowsky, Meghan Higgins and Elisheva Zinberg are doctoral students in
the Physical Therapy Program at Hunter College. They are conducting a research study
examining the effects of wearing a cooling vest on gait endurance in persons with Multiple
Sclerosis (MS). You are being asked to participate in a research study that will help determine if
wearing a cooling garment during ambulation allows persons with MS to walk longer distances.
You were selected for participation because you are a person with MS over 18 years of age who
walks as a regular means of getting around/commuting. There will be an anticipated 15 subjects
that will participate in this research study. Your participation in this study is voluntary. You may
choose to not participate from the start and you may choose to stop at any time during the study.
Procedures
All sessions will take place at the Physical Therapy Department of Hunter College, at 425 east
25th street, basement level. On the first day, you will fill out a demographics questionnaire as
well as a simple fatigue survey and a quality of life scale. You will then be randomly assigned
into a cooled or uncooled group, and will receive the corresponding vest (with or without cooling
capabilities, depending on the group). Wearing the vest, you will perform a timed walking trial,
and then fill out a quick fatigue survey. Each session will last approximately 45 minutes on two
occasions per week for 3 weeks followed by 2 weeks without intervention. You will then repeat
this protocol wearing the other kind of vest, for 3 more weeks.
The study procedures in detail are as follows:
If you agree to participate in the study, you will complete a questionnaire in Hunter
College with the researchers to determine if you are eligible for the study. The screening
will ask questions about your medical history including length of time with MS,
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medications, use of assistive devices for walking such as canes, walkers, or splints, and
whether you have a history of non-MS complications such as a cardiac condition or
orthopedic problems. The researchers will also look at information from your medical
records such as your Expanded Disability Status Scale Score (EDSS) and MS Quality of
Life score (MS QOL-54).
If your responses indicate that you are eligible, you will be asked to participate in this
study.
If you are not eligible to participate, the information obtained from you during screening
will be removed from this study and destroyed/shredded to protect your privacy.
If you are chosen to continue, you will complete one form that will inquire about your
level of fatigue, and another that will inquire about the physical and psychological
impact of MS on your life.
You will then be randomly assigned to one of two groups: cooled or uncooled.
You will receive one of two vests, depending on your assigned group, with or without
cooling capabilities.
After a fifteen minutes seated rest period, you will be asked to perform a single 6-minute
continuous walk. The walk should be performed at your best comfortable pace. You will
be guarded by Dr. Karpatkin for the entire walk. You will also be followed with a
wheelchair by one of the collaborating physical therapy students for the entire walk.
Immediately after completing the walk, you will fill out a fatigue form that asks about
your level of fatigue at that moment. The distance that you walk will be recorded every
minute. You will be asked to perform this timed walk twice a week for the initial 3-week
period.
Following the initial 3-week period, there will be a 2-week detraining period, during
which no walking intervention will take place.
After the 2-week detraining period, you will return and perform the 6-minute walk
wearing the vest that you did not wear during the first 3-week session. If you wore a
cooled vest during the first 3 weeks, you will be asked to perform the walk wearing an
uncooled vest during the second 3-week training period. If you wore an uncooled vest
during the first 3 weeks, you will wear a cooled vest during the second 4-week training
period. As with the first 3-week period, immediately before and after the timed walk,
you will complete the form related to your current level of fatigue. Distances will be
measured in the same manner as previously. You will be free not to answer any item in
any of the questionnaires or forms.
At each visit, please bring with you any walking devices such as canes, walkers, splints
etc. that you would normally use for walking. Please bring the same comfortable
walking shoes to all sessions.
The total time expected for each session is 45 minutes.
None of the procedures or questionnaires in this study is experimental. The only experimental
aspect of this study is the gathering of information for the purpose of analysis.
Risks and/or Discomfort
There are minimal risks to you from participation in this study. You may experience some
fatigue-related discomfort as a result the walking protocol. Because fatigue is the most common
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symptom in persons with MS, it is important to note that any fatigue experienced may be
characteristic of the disease itself, as opposed to a result of the testing conditions. The walking
protocol of this study is not expected to worsen your fatigue, or any other aspect of your MS in
any way. Dr. Karpatkin will walk beside you for the entire walk. You will also be followed by
one of the physical therapy students with a wheelchair. Despite these safeguards, there is a
chance that you could incur an orthopedic injury from the walking or that you may fall and get
injured. If this should occur we will immediately contact your primary care physician and if
necessary take you to the emergency room.
If you feel bothered or upset as a result of participation, or for any reason wish to not continue
you may simply ask to stop and we will immediately end the procedure. You will be free not to
answer any item in any of the questionnaires or forms.
Benefits
There may be no direct benefits to you as an individual. You may experience an increase
awareness of your fatigue levels, and how they may vary based on the use of a cooling garment.
Alternatives
The alternative to this study is not to participate, without repercussions or penalties.
Voluntary Participation: Your participation in this study is voluntary, and you may decide not
to participate without prejudice, penalty, or loss of benefits to which you are otherwise entitled.
If you decide to leave the study, please contact the principal investigator Esther Sosowsky, SPT
at (718)-483-0621 or via email es125@hunter.cuny.edu to inform her of your decision.
Financial Considerations
Other than the cost of travel to and from the Hunter College Brookdale Campus, there will be no
costs incurred by you for participation in the study. You will receive an $80.00 MetroCard to
cover your travel-related expenses. This money does not obligate you to continue the study if at
any point you wish to stop. You may terminate your participation at any time and you will still
receive this compensation.
Confidentiality
The data will be collected using the two fatigue surveys that you fill out and by measuring the
distance walked within each timed walk. Strict confidentiality will be maintained. Knowledge
of your identity and participation in this study will be limited to Dr. Karpatkin, the collaborating
physical therapy students, and the IRB members and staff. Information about your participation
will only be disclosed in the event of an emergency requiring hospitalization, and in such a case
will be disclosed to the treating hospital physician and your primary care physician. Under
expected non-emergency circumstances, no individual identifying information about you will be
disclosed. Where possible, all identifying references about you will be removed and replaced by
a numeric code. Participation in this research is voluntary and involves minimal loss of your
privacy. All questionnaires and data about you that will be used in computer analysis will have
number codes rather than your name. Your name will not be recorded on the information or
reported in any scientific paper or professional meeting to protect your identity. All data will be
reported in aggregate (group) fashion at a professional meeting or in a scientific journal so that
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no one can identify any information about you. If data are used for a publication in the medical
literature or for teaching purposes, no names will be used. A master list of code numbers as well
as all other data pertaining to you and other subjects will be kept confidential by the researchers
and will be stored in a locked file cabinet in the faculty research advisor’s office. Data that will
be used for computer analysis will be kept on a flash drive and only researchers involved in this
study and IRB members and staff will have access to the records and information about this
study. All original hardcopy data will be shredded seven years after completion of the study. The
code key connecting names to numbers will be kept in the research office of Dr. Karpatkin.
Confidentiality will be maintained to the extent allowed by law.
Withdrawal
You may terminate your participation from this study prior to the start or at any time during the
study without penalty, repercussion, or loss of compensation.
Contact Information
If you have questions about the study, you can contact Dr. Karpatkin, at (212) 481-5051. You
should contact the Hunter College Human Research Protection Program (HRPP) Office at
hrpp@hunter.cuny.edu or 212-650-3053, if you have questions regarding your rights as a subject or
if you feel you have been harmed as a result of your participation in this research.
Signatures
I have read (or have had read to me) the contents of this consent forms and have been
encouraged to ask questions. I have received answers to my questions. I have received answers
to my questions. I give my consent to participate in this study. I have received (or will receive) a
copy of this form for my records and future references.

______________________
Participant’s Name

___________________________
Signature

___________
Date

______________________
Researcher’s Name

___________________________
Signature

___________
Date
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APPENDIX D: SCREENING QUESTIONS AND SUBJECT DEMOGRAPHIC
INFORMATION
Screening Questions
Do you have a definitive diagnosis of MS?
Yes
No
Are you able to understand and sign informed consent?
Yes
No
Can you ambulate continuously for six minutes with or without an assistive device?
Yes
No
Do you have any type of orthopedic or cardiopulmonary condition preventing your ability to walk six
minutes?
Yes
No
Have you had a recent exacerbation of your symptoms?
Yes
No
Have you taken steroidal medication within the past 4 weeks?
Yes
No

Subject Demographic Information
Age: __________

Gender: M / F

Date of Birth: __________________

Type of Multiple Sclerosis: _______________________________________________________
Year since diagnosis of Multiple Sclerosis: __________________________________________
Expanded disability status scale (EDSS) Score: ____________________
Fatigue Severity Scale (FSS) Score: ____________________
MSIS Score: ____________________
Use of assistive device: __________________________________________________________
Use of anti-spasticity medications: _________________________________________________
Use of fatigue medication: _______________________________________________________
Use of any other medication: ______________________________________________________
Any other medical Diagnoses: ___________________________________________________

44

APPENDIX E: FATIGUE SEVERITY SCALE (FSS)

Fatigue Severity Scale (FSS)
Your Name
Date:

Date of birth:

This questionnaire contains nine statements that rate the severity of your fatigue symptoms.
Read each statement and circle a number from 1 to 7, based on how accurately it reflects your
condition during the past week and the extent to which you agree or disagree that the statement
applies to you.
***A low value (e.g. 1) indicates strong disagreement with the statement, whereas a high value
(e.g. 7) indicates strong agreement.
During the past week, I have found that:

Disagree

Agree

1. My motivation is lower when I am fatigued

1 2 3 4 5 6 7

2. Exercise brings on my fatigue.

1 2 3 4 5 6 7

3. I am easily fatigued.

1 2 3 4 5 6 7

4. Fatigue interferes with my physical functioning.

1 2 3 4 5 6 7

5. Fatigue causes frequent problems for me.

1 2 3 4 5 6 7

6. My fatigue prevents sustained physical functioning.

1 2 3 4 5 6 7

7. Fatigue interferes with carrying out certain duties and responsibilities.

1 2 3 4 5 6 7

8. Fatigue is among my three most disabling symptoms.

1 2 3 4 5 6 7

9. Fatigue interferes with my work, family or social life.

1 2 3 4 5 6 7

Total Score:
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APPENDIX F: MULTIPLE SCLEROSIS IMPACT SCALE (MSIS-29)


The following questions ask for your views about the impact of MS on your day-to-day life during the
past two weeks



For each statement, please circle the one number that best describes your situation



Please answer all questions

In the past two weeks, how much has your
MS limited your ability to...

Not at
all

A
little

Moderately

Quite a
bit

Extremely

1.

Do physically demanding tasks?

1

2

3

4

5

2.

Grip things tightly (e.g. turning on
taps)?
Carry things?

1

2

3

4

5

1

2

3

4

5

3.

In the past two weeks, how much have you
been bothered by...

Not at
all

A
little

Moderately

Quite a
bit

Extremely

4.

Problems with your balance?

1

2

3

4

5

5.
6.

Difficulties moving about indoors?
Being clumsy?

1
1

2
2

3
3

4
4

5
5

7.

Stiffness?

1

2

3

4

5

8.

Heavy arms and/or legs?

1

2

3

4

5

9.

Tremor of your arms or legs?

1

2

3

4

5

10.

Spasms in your limbs?

1

2

3

4

5

11.

Your body not doing what you want it
to do?
Having to depend on others to do
things for you?

1

2

3

4

5

1

2

3

4

5

12.

Please check that you have answered all the questions before going on to the next page
®2000 Neurological Outcome Measures Unit, 4th Floor Queen Mary Wing, NHNN, Queen
Square, London WC1N 3BG, UK
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In the past two weeks, how much have you
been bothered by...

Not
at all

A
little

Moderately Quite a
bit

Extremely

13. Limitations in your social and leisure
activities at home?
14. Being stuck at home more than you
would like to be?
15. Difficulties using your hands in everyday
tasks?
16. Having to cut down the amount of time
you spent on work or other daily
activities?
17. Problems using transport (e.g. car, bus,
train, taxi, etc.)?
18. Taking longer to do things?

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

19. Difficulty doing things spontaneously (e.g.
going out on the spur of the moment)?
20. Needing to go to the toilet urgently?
21. Feeling unwell?

1

2

3

4

5

1
1

2
2

3
3

4
4

5
5

22. Problems sleeping?

1

2

3

4

5

23. Feeling mentally fatigued?

1

2

3

4

5

24. Worries related to your MS?

1

2

3

4

5

25. Feeling anxious or tense?

1

2

3

4

5

26. Feeling irritable, impatient, or short
tempered?
27. Problems concentrating?

1

2

3

4

5

1

2

3

4

5

28

1

2

3

4

5

1

2

3

4

5

Lack of confidence?

29. Feeling depressed?

Please check that you have circled ONE number for EACH question
 2000 Neurological Outcome Measures Unit, 4th Floor Queen Mary Wing, NHNN, Queen
Square, London WC1N 3BG, UK
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APPENDIX G: DATA ENTRY TABLE
Subject #
VAFS
(mm)

Date

Min 1 (ft.) Min 2 (ft.)

Min 3 (ft.) Min 4 (ft.) Min 5 (ft.) Min 6 (ft.)

TOTAL (ft.)

Cooled
TRIAL 1
TRIAL 2
TRIAL 3
Uncooled
TRIAL 1
TRIAL 2
TRIAL 3

APPENDIX H: VISUAL ANALOG FATIGUE SCALE

Visual Analog Fatigue Scale
Please indicate your current level of fatigue by drawing a vertical line on the scale below

No fatigue

Extremely
severe fatigue
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